CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities:
Net (loss) income	$ (1,080)	$ 6
Adjustments to reconcile net (loss) income to net cash provided by operating activities net of effects of business acquisition:
Depreciation and amortization	2,037	1,160
Stock based compensation	196	102
Provision for doubtful accounts	(166)	(6)
Gain on disposal of property and equipment	(3)	(1)
Unrealized foreign currency gains	(147)
Changes in operating assets and liabilities:
Accounts receivable	(1,477)	(523)
Inventories	63	(51)
Income tax accruals	30	(92)
Prepaid expenses and other assets	(181)	311
Accounts payable	664	35
Accrued expenses	719	(137)
Customer advances	912	1,406
Net cash provided by operating activities	1,567	2,210
Investing activities:
Cash paid in acquisition	(1,271)
Capital expenditures	(4,530)	(926)
Proceeds from sale of equipment		2
Net cash used by investing activities	(5,801)	(924)
Financing activities:
Payments of long-term debt	(1,089)	(167)
Payments of debt issuance costs	(92)
Payments on revolving line of credit	(19,493)	(7,545)
Borrowings on revolving line of credit	20,065	7,545
Borrowing on construction loan	2,012
Borrowing on long-term loan	2,180
Borrowing on capex line of credit	460
Proceeds from exercise of stock options	6	1
Payments on capital lease obligations	(82)	(96)
Net cash provided by (used in) financing activities	3,967	(262)
Net (decrease) increase in cash and cash equivalents	(267)	1,024
Cash and cash equivalents at beginning of period	773	434
Cash and cash equivalents at end of period	506	1,458
Supplemental disclosure of non-cash financing activities:
Cash paid for interest	368	139
Conversion of preferred shares to common shares		$ 1,000
Smithers Avanza Toxicology Services LLC acquisition:
Assets acquired	3,384
Liabilities assumed	(1,719)
Common shares issued	(394)
Cash paid	$ 1,271